2. UroToday Home
  3. Trials in Progress

Trials in Progress

CORE-008: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Trials in Progress
Videos

A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

  • Condition: High-Risk Non-Muscle-Invasive Bladder Cancer
  • Study ID: NCT06567743
View Trial
Conference Coverage
Conference Highlights Written by Physician-Scientist
Presented by Trinity Bivalacqua, MD
The 2025 GU ASCO annual meeting featured a urothelial carcinoma trials in progress session and a presentation by Dr. Trinity Bivalacqua discussing CORE-008, a phase 2, multi-arm, multi-cohort, open-label study to evaluate intravesical cretostimogene grenadenorepvec in participants with high-risk non-muscle invasive bladder cancer.
Presented by Trinity J. Bivalacqua, MD, PhD
 The 2024 SUO annual meeting included a urothelial carcinoma session, featuring a presentation by Dr. Trinity Bivalacqua discussing CORE-008, a phase 2, multi-arm, multi-cohort, open-label study to evaluate the safety and efficacy of cretostimogene grenadenorepvec in participants with high-risk non-muscle invasive bladder cancer (NMIBC).
Press Releases
Official Announcements on Clinical Developments
Cretostimogene grenadenorepvec is a serotype-5 oncolytic adenovirus designed to selectively replicate in cancer cells with retinoblastoma pathway alterations, previously tested as monotherapy in bacillus Calmette–Guérin (BCG)-experienced non-muscle-invasive bladder cancer.